« Return to News | Technology Solutions

Quanterix launches Simoa Single Molecule Array technology

Wednesday, July 31, 2013 11:53 AM

Quanterix, a company focused on high definition diagnostics, has launched its Single Molecule Array (Simoa) technology, making it commercially available for the first time on a fully automated platform for research use only. Simoa enables life science researchers to explore biomarkers and pathways with greater sensitivity and precision, allowing the development of new diagnostic tests and improved treatment of diseases in oncology, neurology and cardiology.

“The diagnostic platform is capable of measuring individual proteins at concentrations 1,000 times lower than the best immunoassays available today,” said Paul Chapman, president and chief executive officer of Quanterix. “We believe that this technology will provide deeper insights into human health that will allow diagnosing, treating and monitoring conditions more effectively than ever before.  Furthermore, through Quanterix’ exclusive partnership with bioMérieux, Simoa will be available for clinical and industrial diagnostic applications. The ambition is to rapidly translate new discoveries made in research today into potentially life-saving diagnostic tests benefiting patients.”

Simoa provides the ability to detect, measure and validate both new and existing biomarkers easily and cost effectively at concentrations previously unattainable.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.